Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05191472 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
A Phase 2 study, sponsored by Alfred Chung, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT05191472 is a Phase 2 study that was terminated before completion, run by Alfred Chung, MD. The registered enrollment target is 3 participants.
The verdict
NCT05191472, a Phase 2 study, was terminated before completion, sponsored by Alfred Chung, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase II trial tests whether pembrolizumab works to shrink tumors in patients with multiple myeloma whose cancer has come back (relapsed) or did not respond to previous treatment (refractory) with anti-BCMA CAR-T therapies. Immunotherapy with pembrolizumab, may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread.
Interventions
- BIOLOGICAL Pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2022-05-03 |
| Est. Completion | 2023-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05191472
The ClinicalTrials.gov registry entry for NCT05191472 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alfred Chung, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT05191472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05191472 about?
NCT05191472 is a clinical study titled "Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies". This phase II trial tests whether pembrolizumab works to shrink tumors in patients with multiple myeloma whose cancer has come back (relapsed) or did not respond to previous treatment (refractory) with anti-BCMA CAR-T therapies. Immunotherapy with pembrolizumab, may induce changes in body's immune s...
What is the current status of trial NCT05191472?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2022-05-03. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT05191472?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05191472?
This trial is sponsored by Alfred Chung, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.